Structural and Physical Basis for Anti-IgE Therapy.

Area of Science:

• Immunology
• Structural Biology
• Biochemistry

Background:

• Omalizumab is an anti-immunoglobulin E (anti-IgE) antibody therapy for severe allergic asthma and chronic idiopathic urticaria.
• It targets IgE but its mechanism for preventing receptor binding remains unclear, despite conflicting structural data.

Purpose of the Study:

• To elucidate the structural and energetic basis of omalizumab's interaction with IgE.
• To explain why omalizumab blocks IgE binding to FcεRI and CD23 receptors.

Main Methods:

• X-ray crystallography to determine the structure of omalizumab-Fab complexed with IgE.
• Computational docking and free energy calculations to analyze binding interactions.
• Mutagenesis studies to identify key IgE residues involved in binding.

Main Results:

• A high-resolution crystal structure of the omalizumab-Fab/IgE complex was determined.
• Structural and energetic analyses revealed distinct binding sites for omalizumab, FcεRI, and CD23 on IgE.
• Omalizumab binding to IgE prevents subsequent receptor engagement by sterically hindering or allosterically altering the receptor-binding epitopes.

Conclusions:

• Omalizumab binding to IgE is incompatible with receptor binding due to distinct, non-overlapping binding sites.
• Key IgE residues crucial for omalizumab, FcεRI, and CD23 interactions were identified.
• This provides a structural and physical rationale for omalizumab's efficacy in treating IgE-mediated allergic conditions.